Immunome, Inc. (IMNM) vs Palvella Therapeutics, Inc. (PVLA)
A side-by-side comparison of Immunome, Inc. and Palvella Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMNM
Immunome, Inc.
$19.87HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
PVLA
Palvella Therapeutics, Inc.
$128.36HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — IMNM vs PVLA
growth of $100 · dividends reinvested · last 2yIMNM +45.7% (+20.7%/yr)PVLA +677.4% (+178.8%/yr)PVLA compounded faster over this window
Log scale — wide-divergence pair
IMNM PVLA
IMNM vs PVLA: by the numbers
- •IMNM is the larger company ($1.90B vs $1.84B market cap).
- •Both run net losses; PVLA's is the smaller (0.00% vs -3059.99% net margin).
Metrics side by side
Valuation
| Metric | IMNM | PVLA |
|---|---|---|
| P/B ratio | 3.62 | 8.49 |
Profitability
| Metric | IMNM | PVLA |
|---|---|---|
| Gross margin | 57.43% | 0.00% |
| Operating margin | -3084.76% | 0.00% |
| Net margin | -3059.99% | 0.00% |
| ROE | -48.43% | -28.45% |
| ROIC | -51.06% | -23.90% |
Growth (annualized)
| Metric | IMNM | PVLA |
|---|---|---|
| Total return CAGR (5Y) | 2.88% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.